Testicular cancer

References

Key articles

Williamson SR, Delahunt B, Magi-Galluzzi C, et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology. 2017 Feb;70(3):335-46. Abstract

Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell tumors. Int J Urol. 2018 Apr;25(4):337-44.Full text  Abstract

Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019 Aug;202(2):272-81.Full text  Abstract

Reference articles

1. Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016 Jul;70(1):93-105. Abstract

2. Williamson SR, Delahunt B, Magi-Galluzzi C, et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology. 2017 Feb;70(3):335-46. Abstract

3. Mostofi FK, Sobin LH; World Health Organization (WHO). Histological typing of testis tumours. Geneva: WHO; 1977. International Histological Classification of Tumours, No 16.

4. Amin MB, Edge S, Green F, et al. AJCC cancer staging manual. 8th ed. (2017). Cham, Switzerland: Springer International; 2017.

5. Brierley JD, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control (UICC). TNM classification of malignant tumors. 8th ed. Chichester: Wiley-Blackwell; 2017.

6. Pottern LM, Goedert JJ. Epidemiology of testicular cancer. In: Javadpour N, ed. Principles and management of testicular cancer. New York, NY: Thieme; 1986:107-119.

7. Oosting SF, de Haas EC, Links TP, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol. 2010 Jan;21(1):104-8. Abstract

8. Daniels IR, Layer GT. Testicular tumours presenting as gynaecomastia. Eur J Surg Oncol. 2003 Jun;29(5):437-9. Abstract

9. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.Full text  Abstract

10. Znaor A, Lortet-Tieulent J, Laversanne M, et al. International testicular cancer incidence trends: generational transitions in 38 countries 1900-1990. Cancer Causes Control. 2015 Jan;26(1):151-8. Abstract

11. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: testicular cancer. 2022 [internet publication].Full text

12. Schaffar R, Pant S, Bouchardy C, et al. Testicular cancer in Geneva, Switzerland, 1970-2012: incidence trends, survival and risk of second cancer. BMC Urol. 2019 Jul 10;19(1):64.Full text  Abstract

13. Dearnaley DP, Huddart RA, Horwich A. Managing testicular cancer. BMJ. 2001 Jun 30;322(7302):1583-8.Full text  Abstract

14. Trabert B, Chen J, Devesa SS, et al. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology. 2015 Jan;3(1):4-12.Full text  Abstract

15. Fukawa T, Kanayama HO. Current knowledge of risk factors for testicular germ cell tumors. Int J Urol. 2018 Apr;25(4):337-44.Full text  Abstract

16. DeSantis CE, Miller KD, Goding Sauer A, et al. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019 May;69(3):211-33.Full text  Abstract

17. Rajpert-de Meyts E, Hoei-Hansen CE. From gonocytes to testicular cancer: the role of impaired gonadal development. Ann N Y Acad Sci. 2007 Dec;1120:168-80. Abstract

18. Wang Z, McGlynn KA, Rajpert-De Meyts E, et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. Nat Genet. 2017 Jul;49(7):1141-7.Full text  Abstract

19. Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997;65:284-297. Abstract

20. Tyldesley S, Voduc D, McKenzie M, et al. Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology. 2006;67:594-598. Abstract

21. Ronnen EA, Kondagunta GV, Bacik J, et al. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. J Clin Oncol. 2005;23:6999-7004. Abstract

22. Buetow SA. Epidemiology of testicular cancer. Epidemiol Rev. 1995;17(2):433-49. Abstract

23. Sokal M, Peckham MJ, Hendry WF. Bilateral germ cell tumours of the testis. Br J Urol. 1980 Apr;52(2):158-62. Abstract

24. Coupland CA, Chilvers CE, Davey G, et al. Risk factors for testicular germ cell tumours by histological tumour type. United Kingdom Testicular Cancer Study Group. Br J Cancer. 1999 Aug;80(11):1859-63. Abstract

25. Reuter VE. Origins and molecular biology of testicular germ cell tumors. Mod Pathol. 2005 Feb;18 Suppl 2:S51-60. Abstract

26. Loveday C, Law P, Litchfield K, et al. Large-scale analysis demonstrates familial testicular cancer to have polygenic aetiology. Eur Urol. 2018 Sep;74(3):248-52.Full text  Abstract

27. Richiardi L, Akre O, Montgomery SM, et al. Fecundity and twinning rates as measures of fertility before diagnosis of germ-cell testicular cancer. J Natl Cancer Inst. 2004 Jan 21;96(2):145-7.Full text  Abstract

28. Dong C, Lonnstedt I, Hemminki K Familial testicular cancer and second primary cancers in testicular cancer patients by histological type. Eur J Cancer. 2001 Oct;37(15):1878-85. Abstract

29. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997 Nov 15;80(10):1954-60. Abstract

30. Zequi Sde C, da Costa WH, Santana TB, et al. Bilateral testicular germ cell tumours: a systematic review. BJU Int. 2012 Oct;110(8):1102-9.Full text  Abstract

31. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007853.Full text  Abstract

32. Strohsnitter WC, Noller KL, Hoover RN, et al. Cancer risk in men exposed in utero to diethylstilbestrol. J Natl Cancer Inst. 2001 Apr 4;93(7):545-51.Full text  Abstract

33. Powles T, Bower M, Daugaard G, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol. 2003 May 15;21(10):1922-7. Abstract

34. Adami HO, Bergstrom R, Mohner M, et al. Testicular cancer in nine northern European countries. Int J Cancer. 1994 Oct 1;59(1):33-8. Abstract

35. Jacobsen R, Bostofte E, Engholm G, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ. 2000 Sep 30;321(7264):789-92.Full text  Abstract

36. Guo J, Pukkala E, Kyyronen P, et al. Testicular cancer, occupation and exposure to chemical agents among Finnish men in 1971-1995. Cancer Causes Control. 2005 Mar;16(2):97-103. Abstract

37. Pukkala E, Weiderpass E. Socio-economic differences in incidence rates of cancers of the male genital organs in Finland, 1971-95. Int J Cancer. 2002 Dec 20;102(6):643-8. Abstract

38. Pettersson A, Richiardi L, Nordenskjold A, et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007 May 3;356(18):1835-41.Full text  Abstract

39. Baird DC, Meyers GJ, Hu JS. Testicular Cancer: Diagnosis and Treatment. Am Fam Physician. 2018 Feb 15;97(4):261-268. Abstract

40. Ye H, Ulbright TM. Difficult differential diagnoses in testicular pathology. Arch Pathol Lab Med. 2012 Apr;136(4):435-46. Abstract

41. Dogra V, Bhatt S. Acute painful scrotum. Radiol Clin North Am. 2004 Mar;42(2):349-63. Abstract

42. Marcell AV, Bell DL, Joffe A; Society for Adolescent Health and Medicine, SAHM Male Health Special Interest Group. The male genital examination: a position paper of the Society for Adolescent Health and Medicine. J Adolesc Health. 2012 Apr;50(4):424-5. Abstract

43. Richie JP. Neoplasms of the testis. In: Walsh PC, Retik AB, Vaughan ED, et al., eds. Campell's urology. 7th ed. Philadelphia, PA: WB Saunders Company; 2001:2417-8.

44. American College of Radiology. ACR appropriateness criteria: Newly diagnosed palpable scrotal abnormality. 2021 [internet publication].Full text

45. Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. J Urol. 2019 Aug;202(2):272-81.Full text  Abstract

46. European Association of Urology. Testicular cancer. 2022 [internet publication].Full text

47. Oldenburg J, Berney DM, Bokemeyer C, et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Apr;33(4):362-75.Full text  Abstract

48. Sohaib SA, Cook G, Koh DM. Imaging studies for germ cell tumors. Hematol Oncol Clin North Am. 2011 Jun;25(3):487-502, vii. Abstract

49. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec;54(12):e11-79.Full text  Abstract

50. Stenman UH, Lamerz R, Looijenga LH. Tumor markers in testicular cancers. In: The National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. 2009 [internet publication].Full text

51. Lawton A, Mead G. Staging and prognostic factors in testicular cancer. Semin Surg Oncol. 1999 Dec;17(4):223-9. Abstract

52. Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer. 2002 Sep 15;95(6):1228-33. Abstract

53. Oosting SF, de Haas EC, Links TP, et al. Prevalence of paraneoplastic hyperthyroidism in patients with metastatic non-seminomatous germ-cell tumors. Ann Oncol. 2010 Jan;21(1):104-8. Abstract

54. Street E, Joyce A, Wilson J. BASHH UK guideline for the management of epididymo-orchitis, 2010. Int J STD AIDS. 2011 Jul;22(7):361-5.Full text  Abstract

55. Sandlow JI, Winfield HN, Goldstein M. Surgery of the scrotum and seminal vesicles. In: Wein AJ, Kavoussi LR, Novick AC, et al, eds. Campbell-Walsh urology. 9th ed. Philadelphia, PA: WB Saunders; 2007:1105-6.

56. Bhatt S, Jafri SZ, Wasserman N, et al. Imaging of non-neoplastic intratesticular masses. Diagn Interv Radiol. 2011 Mar;17(1):52-63.Full text  Abstract

57. Kingston M, French, Higgins S, et al. UK national guidelines on the management of syphilis 2015. Int J STD AIDS. 2016 May;27(6):421-46.Full text  Abstract

58. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997 Feb;15(2):594-603.Full text  Abstract

59. US Preventive Services Task Force. Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2011 Apr 5;154(7):483-6.Full text  Abstract

60. Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005 Dec 20;23(36):9290-4. Abstract

61. Mead GM, Fossa SD, Oliver RT, et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011 Feb 2;103(3):241-9.Full text  Abstract

62. Aydin AM, Zemp L, Cheriyan SK, et al. Contemporary management of early stage testicular seminoma. Transl Androl Urol. 2020 Jan;9(suppl 1):S36-44.Full text  Abstract

63. Warde PR, Chung P, Sturgeon J, et al. Should surveillance be considered the standard of care in stage I seminoma? J Clin Oncol (Meeting Abstracts). 2005;23(suppl 16):abstr 4520.Full text

64. Petrelli F, Coinu A, Cabiddu M, et al. Surveillance or adjuvant treatment with chemotherapy or radiotherapy in stage I seminoma: a systematic review and meta-analysis of 13 studies. Clin Genitourin Cancer. 2015 Oct;13(5):428-34. Abstract

65. Patel HD, Srivastava A, Alam R, et al. Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. Urol Oncol. 2017 Oct;35(10):606.e1-7. Abstract

66. Hamilton RJ, Canil C, Shrem NS, et al. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. Can Urol Assoc J. 2022 Jun;16(6):155-73.Full text  Abstract

67. Heinzelbecker J, Schmidt S, Lackner J, et al. Therapy of clinical stage IIA and IIB seminoma: a systematic review. World J Urol. 2021 Nov 15 [Epub ahead of print].Full text  Abstract

68. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma. J Clin Oncol. 1999 Apr;17(4):1146. Abstract

69. Chung P, Warde P. Testicular cancer: germ cell tumours. BMJ Clin Evid. 2016 Jan 7;2016. pii: 1807.Full text  Abstract

70. Cohn-Cedermark G, Stahl O, Tandstad T, et al. Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Andrology. 2015 Jan;3(1):102-10.Full text  Abstract

71. Tyrrell HEJ, Church DN, Joseph J, et al. Changing practice evaluation-stage 1 seminoma: outcomes with adjuvant treatment versus surveillance: risk factors for recurrence and optimizing follow-up protocols-experience from a supraregional center. Clin Genitourin Cancer. 2018 Jun;16(3):240-4. Abstract

72. Chung P, Mayhew LA, Warde P, et al. Management of stage I seminomatous testicular cancer: a systematic review. Clin Oncol (R Coll Radiol). 2010 Feb;22(1):6-16. Abstract

73. Daugaard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014 Dec 1;32(34):3817-23. Abstract

74. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS. 2003 Jan;111(1):76-83. Abstract

75. Brewster SF. Challenging the EAU 2009 guidelines on testis cancer: the risk-adapted management of stage I nonseminomatous germ cell tumours: surveillance yields equal results with less toxicity. Euro Urol. 2010 Apr;9(3):459-61.Full text

76. Cullen M, Huddart R, Joffe J, et al. The 111 study: a single-arm, phase 3 trial evaluating one cycle of bleomycin, etoposide, and cisplatin as adjuvant chemotherapy in high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis. Eur Urol. 2020 Mar;77(3):344-51.Full text  Abstract

77. Calabrò F, Albers P, Bokemeyer C, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol. 2012 Jun;61(6):1212-21. Abstract

78. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors. J Clin Oncol. 1989 Mar;7(3):387-91. Abstract

79. Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014 Dec;15(13):1442-50.Full text  Abstract

80. Daneshmand S, Albers P, Fosså SD, et al. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012 Nov;62(5):867-76. Abstract

81. Cathomas R, Klingbiel D, Bernard B, et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group registry. J Clin Oncol. 2018 Oct 4;JCO1800210.Full text  Abstract

82. Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998 Jul;16(7):2500-4. Abstract

83. Bokemeyer C, Schmoll HJ, Ludwig E, et al. The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. Br J Cancer. 1994 May;69(5):863-7.Full text  Abstract

84. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage in patients with relapsed testicular cancer. J Clin Oncol. 2000 Oct 1;18(19):3346-51. Abstract

85. Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012 Mar 10;30(8):800-5. Abstract

86. Incrocci L, Hop WC, Wijnmaalen A, et al. Treatment outcome, body image and sexual functioning after orchiectomy and radiotherapy for stage I-II testicular seminoma. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1165-73. [Erratum in: Int J Radiat Oncol Biol Phys. 2003 Sep-Oct;21(5):418.] Abstract

87. Warszawski N, Schmucking M. Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy. Scand J Urol Nephrol. 1997 Aug;31(4):355-9. Abstract

88. Hermans BP, Sweeney CJ, Foster RS, et al. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol. 2000 Jun;163(6):1721-4. Abstract

89. Stephenson AJ, Sheinfeld J. Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol. 2005 Sep;6(5):367-77. Abstract

90. Kondagunta GV, Sheinfeld J, Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol. 2004 Feb 1;22(3):464-7. Abstract

91. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide with either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors. J Clin Oncol. 1998 Apr;16(4):1287-93. Abstract

92. Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer. J Clin Oncol. 1997 May;15(5):1844-52. Abstract

93. Voss MH, Feldman DR, Bosl GJ, et al. A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematol Oncol Clin North Am. 2011 Jun;25(3):557-76, viii -ix.Full text  Abstract

94. Mazumdar M, Bajorin DF, Bacik J, et al. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol. 2001 May 1;19(9):2534-41. Abstract

95. Lauritsen J, Hansen MK, Bandak M, et al. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. J Clin Oncol. 2020 Feb 20;38(6):584-592.Full text  Abstract

96. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010 Oct 20;28(30):4649-57.Full text  Abstract

97. Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012 Jan 20;30(3):300-7. Abstract

98. Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011 Sep;60(3):516-26. Abstract

99. Kerns SL, Fung C, Monahan PO, et al. Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study. J Clin Oncol. 2018 May 20;36(15):1505-12.Full text  Abstract

100. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Jul 1;36(19):1994-2001.Full text  Abstract

101. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003 Jun 15;97(12):3090-8. Abstract

102. Groot HJ, Lubberts S, de Wit R, et al. Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. J Clin Oncol. 2018 Aug 20;36(24):2504-13.Full text  Abstract

Use of this content is subject to our disclaimer